Browse hierarchy: [Microbiology (MI)](/submissions/MI) → [Subpart D — Serological Reagents](/submissions/MI/subpart-d%E2%80%94serological-reagents) → [21 CFR 866.3210](/submissions/MI/subpart-d%E2%80%94serological-reagents/866.3210) → NTM — Antigen, Inflammatory Response Marker, Sepsis

# NTM · Antigen, Inflammatory Response Marker, Sepsis

_Microbiology · 21 CFR 866.3210 · Class 2_

**Canonical URL:** https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/NTM

## Overview

- **Product Code:** NTM
- **Device Name:** Antigen, Inflammatory Response Marker, Sepsis
- **Regulation:** [21 CFR 866.3210](/submissions/MI/subpart-d%E2%80%94serological-reagents/866.3210)
- **Device Class:** 2
- **Review Panel:** [Microbiology](/submissions/MI)

## Identification

An endotoxin assay is a device that uses serological techniques in whole blood. The device is intended for use in conjunction with other laboratory findings and clinical assessment of the patient to aid in the risk assessment of critically ill patients for progression to severe sepsis.

## Classification Rationale

Class II (special controls). The special control for this device is the FDA guidance entitled “Class II Special Controls Guidance Document: Endotoxin Assay.” See § 866.1(e) for the availability of this guidance document.

## Special Controls

*Classification.* Class II (special controls). The special control for this device is the FDA guidance entitled “Class II Special Controls Guidance Document: Endotoxin Assay.” See § 866.1(e) for the availability of this guidance document.

## Recent Cleared Devices (3 of 3)

| Record | Device Name | Applicant | Decision Date | Decision |
| --- | --- | --- | --- | --- |
| [K070310](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/NTM/K070310.md) | B R A H M S PCT SENSITIVE KRYPTOR TEST SYSTEM | Brahms Aktiengesellschaft | Mar 31, 2008 | SESE |
| [K071146](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/NTM/K071146.md) | VIDAS B.R.A.H.M.S. PCT ASSAY | bioMerieux, Inc. | Oct 11, 2007 | SESE |
| [K040887](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/NTM/K040887.md) | B-R-A-H-M-S PCT LIA | Brahms Aktiengesellschaft | Jan 7, 2005 | SESE |

## Top Applicants

- Brahms Aktiengesellschaft — 2 clearances
- bioMerieux, Inc. — 1 clearance

---

**Source:** [https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/NTM](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/NTM)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com